US: Conflicting Evidence Of mRNA Technology Raises Serious Concerns About Rush For Use In New Vaccine Development
Authored by Megan Redshaw via The Epoch Times
The U.S. government and pharmaceutical companies are investing a substantial amount to develop new mRNA vaccines for infectious diseases and cancer, fueling a lucrative mRNA platform valued at $136.2 billion.
A newly established White House program announced on Aug. 23 that it is granting a total of $25 million over three years to Emory University, Yale School of Medicine, and the University of Georgia to develop personalized therapeutic vaccines against cancers and emerging infections, similar to how COVID-19 mRNA vaccines target SARS-CoV-2. They aim to use mRNA—an essential element in COVID-19 vaccines developed to prevent SARS-CoV-2 infections—to program a unique class of immune cells called dendritic cells to initiate a desired immunological response.
Pharmaceutical companies such as Moderna, BioNTech, and CureVac are conducting clinical trials using mRNA-based vaccines with advanced melanoma, ovarian, colorectal, and pancreatic cancers. The National Institutes of Health is partnering with BioNTech to develop a personalized vaccine for pancreatic cancers. In addition to COVID-19 and cancer, other mRNA-based vaccines in development target influenza, genital herpes, respiratory viruses, and shingles.
Although mRNA platforms are appealing because they reduce costs and shorten the vaccine development timeline, evidence and experience suggest the mRNA technology used for novel COVID-19 vaccines is associated with various harms and neither prevents COVID-19 nor its transmission.
The unprecedented rates of adverse events following COVID-19 vaccination overshadow the benefits, according to researchers from Australia who say the SARS-CoV-2 spike protein, whether from the virus or created from genetic code in mRNA and adenovectorDNA vaccines, is toxic and causes a wide array of diseases.
In their recently published paper published in Biomedicines titled, “‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA,” the researchers explored peer-reviewed data countering the “safe and effective” narrative attached to new technologies used to develop mRNA and adenovectorDNA vaccines at “warp speed” to end the pandemic.
Spike protein pathogenicity, termed “spikeopathy,” describes the ability of the spike protein to cause disease, and the researchers say it can affect many organ systems.
Researchers noted the following key problem areas:
- Spike protein toxicity (spikeopathy) from both the virus and when produced by gene codes in people vaccinated with COVID-19 vaccines.
- Inflammatory properties in specific lipid nanoparticles (LNPs) used to transport mRNA.
- Long-lasting action caused by N1-methyl pseudouridine in the synthetic mRNA—also referred to as modRNA.
- Widespread distribution of mRNA and DNA codes via the LNP and viral vector carrier matrices, respectively.
- Human cells produce a foreign protein that can cause autoimmunity.
